Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Dr. Christian Torp-Pedersen is scheduled to present detailed findings from the Phase 2b clinical trial of vernakalant (oral) at the European Society of Cardiology (ESC) Congress 2009, being held in Barcelona, Spain from August 29 to September 2, 2009. The presentation, titled "Oral vernakalant for the prevention of atrial fibrillation recurrence post-cardioversion," is scheduled for Monday, August 31, 2009 at 4:45pm local time.
Positive top-line results from the Phase 2b trial were originally announced in July 2008. The 735-patient double-blind, placebo-controlled, randomized, dose-ranging study was designed to explore safety and tolerability, pharmacokinetics and efficacy of vernakalant (oral) over 90 days of dosing in patients at risk of recurrent atrial fibrillation.